Prelude Therapeutics To Participate in Jefferies Healthcare Conference
May 31, 2023 08:30 ET
|
Prelude Therapeutics, Inc.
WILMINGTON, Del., May 31, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the company will...
Prelude Therapeutics Announces Pricing of Public Offering
May 18, 2023 07:00 ET
|
Prelude Therapeutics, Inc.
WILMINGTON, Del., May 18, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated ("Prelude" or the "Company") (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced the...
Prelude Therapeutics Announces Launch of Proposed Public Offering
May 17, 2023 16:08 ET
|
Prelude Therapeutics, Inc.
WILMINGTON, Del., May 17, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (“Prelude” or the “Company”) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that it...
Prelude Therapeutics Announces First Quarter 2023 Financial Results and Operations Update
May 08, 2023 08:30 ET
|
Prelude Therapeutics, Inc.
Eight abstracts presented at AACR 2023 demonstrate progress of the pipeline Cash runway unchanged, supporting operations into the fourth quarter of 2024 WILMINGTON, Del., May 08, 2023 (GLOBE...
Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in May
April 27, 2023 08:30 ET
|
Prelude Therapeutics, Inc.
WILMINGTON, Del., April 27, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that company executives will...
Prelude Therapeutics to Present at American Association for Cancer Research 2023 Conference
April 11, 2023 08:30 ET
|
Prelude Therapeutics, Inc.
WILMINGTON, Del., April 11, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced details relating to eight...
Prelude Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update
March 15, 2023 08:30 ET
|
Prelude Therapeutics, Inc.
Four differentiated clinical compounds progressing through Phase 1 towards key data milestones Eight abstracts accepted for presentation at the 2023 American Association for Cancer Research (AACR)...
Prelude Therapeutics Announces Clinical Trial Collaboration with BeiGene to Evaluate PRT2527 in Combination with Zanubrutinib in Hematologic Cancers
March 15, 2023 08:00 ET
|
Prelude Therapeutics, Inc.
WILMINGTON, Del., March 15, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced a clinical trial...
Prelude Therapeutics To Participate in Barclays Global Healthcare Conference
March 01, 2023 08:30 ET
|
Prelude Therapeutics, Inc.
WILMINGTON, Del., March 01, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the company will...
Prelude Therapeutics To Participate in Two Upcoming Healthcare Investor Conferences
February 09, 2023 09:05 ET
|
Prelude Therapeutics, Inc.
WILMINGTON, Del., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the company will...